Foghorn Therapeutics Inc.
FHTX
$4.88
-$0.18-3.56%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 30.91M | 24.52M | 24.17M | 23.50M | 22.60M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.91M | 24.52M | 24.17M | 23.50M | 22.60M |
| Cost of Revenue | 85.47M | 83.93M | 88.62M | 90.62M | 94.53M |
| Gross Profit | -54.56M | -59.41M | -64.44M | -67.12M | -71.93M |
| SG&A Expenses | 27.55M | 27.11M | 27.43M | 27.89M | 28.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 113.02M | 111.03M | 116.04M | 118.51M | 122.89M |
| Operating Income | -82.11M | -86.52M | -91.87M | -95.00M | -100.29M |
| Income Before Tax | -74.28M | -72.12M | -75.40M | -80.44M | -86.62M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -74.28 | -72.12 | -75.40 | -80.44 | -86.62 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -74.28M | -72.12M | -75.40M | -80.44M | -86.62M |
| EBIT | -82.11M | -86.52M | -91.87M | -95.00M | -100.29M |
| EBITDA | -78.78M | -83.23M | -88.70M | -91.89M | -97.17M |
| EPS Basic | -1.18 | -1.15 | -1.20 | -1.36 | -1.65 |
| Normalized Basic EPS | -0.69 | -0.72 | -0.75 | -0.82 | -1.00 |
| EPS Diluted | -1.18 | -1.15 | -1.20 | -1.36 | -1.65 |
| Normalized Diluted EPS | -0.69 | -0.72 | -0.75 | -0.82 | -1.00 |
| Average Basic Shares Outstanding | 251.92M | 251.73M | 251.30M | 239.90M | 219.48M |
| Average Diluted Shares Outstanding | 251.92M | 251.73M | 251.30M | 239.90M | 219.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |